Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$59.18 USD
-1.25 (-2.07%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $59.17 -0.01 (-0.02%) 7:34 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$59.18 USD
-1.25 (-2.07%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $59.17 -0.01 (-0.02%) 7:34 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Zacks News
Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 42.19% and 307.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should iShares Russell 2000 ETF (IWM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWM
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Halozyme Therapeutics (HALO) Down 34.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Strength Seen in Halozyme Therapeutics (HALO): Can Its 5.3% Jump Turn into More Strength?
by Zacks Equity Research
Halozyme Therapeutics (HALO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Halozyme Therapeutics (HALO) stock based on the movements in the options market lately.
Should Vanguard Russell 2000 ETF (VTWO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VTWO
Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWO
Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VTWG
Halozyme (HALO) Q4 Earnings Top, Revenues Miss, Stock Down
by Zacks Equity Research
Halozyme Therapeutics (HALO) reports mixed fourth-quarter results. Stock is down in the after-market hours in response to the earnings results.
Halozyme Therapeutics (HALO) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 2.13% and 2.46%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in Halozyme (HALO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Halozyme (HALO) stock based on the movements in the options market lately.
Should iShares Russell 2000 ETF (IWM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWM
Market on Tipping Point of New Bull Trend: These 5 Charts Illustrate Why
by Andrew Rocco
You never really know when a new bull trend has arrived for sure. However, by looking at different sides of the market you can begin to put the pieces of the puzzle together.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Halozyme (HALO) Down 9.2% on Weak 2023 Financial Guidance
by Zacks Equity Research
Though Halozyme (HALO) expects a year-over-year increase in revenues and earnings for 2023, the company's guidance fell short of Wall Street expectations.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWO
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks.com featured highlights Halozyme Therapeutics, Arista Networks and Citizens Financial Group
by Zacks Equity Research
Halozyme Therapeutics, Arista Networks and Citizens Financial Group have been highlighted in this Screen of The Week article.
3 Stocks to Keep an Eye on for Earnings Growth in 2023
by Tirthankar Chakraborty
As 2023 approaches, its prudent to have a look at stocks like Halozyme Therapeutics (HALO), Arista Networks (ANET) & Citizens Financial Group (CFG) for solid earnings growth.
Halozyme Therapeutics (HALO) Up 16.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Halozyme (HALO) Stock Rises 35% in the Year so Far: Here's Why
by Zacks Equity Research
Halozyme (HALO) is gaining on its proprietary drug delivery technology, ENHANZE. It expects strong revenues on the back of robust demand for its new partnered drugs.